Maze Therapeutics, Inc.

MAZE

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001842295

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $397.1M
Warnings	thin data not computable: dilution, degenerate inputs, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Mar 25, 2026 229 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$34.16 2026-11-06; market equity $1.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 25, 2026

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	not computable	(6.6%)			
a prior annual assets observation is required					
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 16.2					
Twelve-month failure probability	0.05%	0.08%	29.8	249	2026-06-30
Altman Z double-prime	7.81	(0.37)	12.3	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	15.50x	2.94x	6.3	828	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	10.0%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
a prior annual working-capital observation is required					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 1					
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 1					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.4%)	(2.1%)	39
Distance from 52-week high	(34.0%)	(30.4%)	46
EBIT to enterprise value	(8.2%)	(1.5%)	37
Free cash flow yield	(5.9%)	(1.0%)	39
Book value to price	0.24	0.29	45
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(0.36)	(0.19)	39

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$202.6M
Operating cash flow, four quarters	-$106.5M
Months of runway	22.8
Days since last periodic filing	90 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$15.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$131.1M	2025-12-31	2026-03-25	10-K	26-122778
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$111.9M	2025-12-31	2026-03-25	10-K	26-122778
3	assets	us-gaap:Assets	$397.1M	2025-12-31	2026-03-25	10-K	26-122778
4	current assets	us-gaap:AssetsCurrent	$349.7M	2025-12-31	2026-03-25	10-K	26-122778
5	current liabilities	us-gaap:LiabilitiesCurrent	$22.6M	2025-12-31	2026-03-25	10-K	26-122778
6	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$489.5M	2025-12-31	2026-03-25	10-K	26-122778
7	operating income	us-gaap:OperatingIncomeLoss	-$142.9M	2025-12-31	2026-03-25	10-K	26-122778
8	book equity	us-gaap:StockholdersEquity	$355.0M	2025-12-31	2026-03-25	10-K	26-122778
9	liabilities	us-gaap:Liabilities	$42.2M	2025-12-31	2026-03-25	10-K	26-122778
10	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$794,000	2025-12-31	2026-03-25	10-K	26-122778
11	depreciation amortization	us-gaap:Depreciation	$2.4M	2025-12-31	2026-03-25	10-K	26-122778
12	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$131.1M	2025-12-31	2026-03-25	10-K	26-122778
13	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-25	10-K	26-122778
14	shares outstanding	us-gaap:CommonStockSharesOutstanding	49,335,551	2025-12-31	2026-03-25	10-K	26-122778

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.